Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziltivekimab in Acute Myocardial Infarction
NCT06118281Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2024
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of ziltivekimab in acute myocardial infarction (AMI), sponsored by Novo Nordisk. Started Jun 2024; status: active, not recruiting.
02
Drugs
ziltivekimab
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT06118281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118281.